Outcomes of patients with bleeding in the gastrointestinal tract, following treatment with Hemospray

Outcomes from an international multi-centre registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN29594250

Enrollment

10000

Registered

2018-09-05

Start date

2016-12-26

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal bleeding Digestive System Gastrointestinal bleeding

Interventions

Participants were treated with Hemospray after endoscopic procedures as per routine clinical practice and their clinical records were observed for a 30 day period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older 2. Gastrointestinal bleeding

Exclusion criteria

Exclusion criteria: 1. Allergic to Hemospray 2. Known perforation

Design outcomes

Primary

Measure	Time frame
Endoscopic hemostasis of gastrointestinal bleeding when Hemospray is used on its own as monotherapy, dual therapy or rescue therap within 5 minutes of application of Hemospray.	—

Secondary

Measure	Time frame
The following are tracked over the 30 days of observation of hospital records: 1. Re-bleeding in less than 24 hours post initial endoscopy, at 24-72 hours, 4-7 days, 7-14 days and more than 14 days after the initial endoscopic therapy with Hemospray 2. 7 day and 30 day all-cause mortality 3. Baseline pathology and disease specific outcomes 4. Adverse events	—

Countries

France, Germany, United Kingdom, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026